News
We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...
The convergence of AI with biotechnology has ushered in an era of innovation in drug development, genomics, and diagnostics.
Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421. Mar. 24, 2025 11:45 PM ET Sana Biotechnology, Inc. (SANA) Stock SANA 5 Comments. Myriam Alvarez. 2.64K Followers. Follow.
In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical industry to China. Though we have long stood as the global leader in ...
Fidelity Advisor Biotechnology Fund earns an Average Process Pillar rating. The main driver of the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's ...
The National Security Commission on Emerging Biotechnology (NSCEB) announced on April 8, 2025, the availability of its final report and action plan, “urging Congressional action to bring the ...
U.S. biotechnology needs urgent upgrades, National Commission says | UDaily - University of Delaware
The National Biotechnology Initiative Act of 2025, legislation that would implement key recommendations of the report, was introduced earlier this month in the House and the Senate by the commission’s ...
Fidelity Select Biotechnology Portfolio earns an Average Process Pillar rating. The predominant contributor to the rating is its parent firm's superior long-term risk-adjusted performance, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results